Acquired (autoimmune) hemophilia (AHA) is a rare and serious bleeding disorder caused by autoantibodies that target coagulation factor VIII. This condition can be life-threatening due to spontaneous bleeding and is often diagnosed in adults, particularly in older people. Understanding its demographics, outcomes, and readmission rates is crucial for improving patient care and management, according to research published this month in Blood Vessels, Thrombosis & Hemostasis .

Despite significant advancements in therapy elements, there is limited evidence regarding the epidemiology and outcomes of these AHA treatments in a broader population. Aditi Sharma, from the Karmanos Cancer Institute at Wayne State University School of Medicine, and colleagues aimed to shed light on the epidemiology

See Full Page